Treatment with anakinra, a recombinant IL-1 receptor antagonist, partially inhibited NET production, determined by co-staining with MPO and DAPI, from control PMNs treated with synovial fluid from patient with gout (Fig 5). This evidence concerns the gene MPO and gout.